|
1
|
Zaal EA and Berkers CR: The influence of
metabolism on drug response in cancer. Front Oncol. 8:5002018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Warburg O, Wind F and Negelein E: The
metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonuccelli G, Whitaker-Menezes D,
Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK,
Vander Heiden MG, Migneco G, Chiavarina B, et al: The reverse
Warburg effect: Glycolysis inhibitors prevent the tumor promoting
effects of caveolin-1 deficient cancer associated fibroblasts. Cell
Cycle. 9:1960–1971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boumahdi S and de Sauvage FJ: The great
escape: Tumour cell plasticity in resistance to targeted therapy.
Nat Rev Drug Discov. 19:39–56. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gershon O, Ezenwa NE and Osabohien R:
Implications of oil price shocks on net oil-importing African
countries. Heliyon. 5:e022082019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Woo YM, Shin Y, Lee EJ, Lee S, Jeong SH,
Kong HK, Park EY, Kim HK, Han J, Chang M and Park JH: Inhibition of
aerobic glycolysis represses Akt/mTOR/HIF-1α axis and restores
tamoxifen sensitivity in antiestrogen-resistant breast cancer
cells. PLoS One. 10:e01322852015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Komurov K, Tseng JT, Muller M, Seviour EG,
Moss TJ, Yang L, Nagrath D and Ram PT: The glucose-deprivation
network counteracts lapatinib-induced toxicity in resistant
ErbB2-positive breast cancer cells. Mol Syst Biol. 8:5962012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruprecht B, Zaal EA, Zecha J, Wu W,
Berkers CR, Kuster B and Lemeer S: Lapatinib resistance in breast
cancer cells is accompanied by phosphorylation-mediated
reprogramming of glycolysis. Cancer Res. 77:1842–1853. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y,
Ji F, Qian H, Gan D, Yue S, et al: The miR-186-3p/EREG axis
orchestrates tamoxifen resistance and aerobic glycolysis in breast
cancer cells. Oncogene. 38:5551–5565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Apicella M, Giannoni E, Fiore S, Ferrari
KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A,
Comoglio PM, et al: Increased lactate secretion by cancer cells
sustains non-cell-autonomous adaptive resistance to MET and EGFR
targeted therapies. Cell Metab. 28:848–865 e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varghese E, Samuel SM, Liskova A, Samec M,
Kubatka P and Busselberg D: Targeting glucose metabolism to
overcome resistance to anticancer chemotherapy in breast cancer.
Cancers (Basel). 12:22522020. View Article : Google Scholar
|
|
14
|
Liu X, Miao W, Huang M, Li L, Dai X and
Wang Y: Elevated hexokinase II expression confers acquired
resistance to 4-hydroxytamoxifen in breast cancer cells. Mol Cell
Proteomics. 18:2273–2284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krasnov GS, Dmitriev AA, Lakunina VA,
Kirpiy AA and Kudryavtseva AV: Targeting VDAC-bound hexokinase II:
A promising approach for concomitant anti-cancer therapy. Expert
Opin Ther Targets. 17:1221–1233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang T, Ren C, Qiao P, Han X, Wang L, Lv
S, Sun Y, Liu Z, Du Y and Yu Z: Correction: PIM2-mediated
phosphorylation of hexokinase 2 is critical for tumor growth and
paclitaxel resistance in breast cancer. Oncogene. 39:720–721. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang T, Ren C, Qiao P, Han X, Wang L, Lv
S, Sun Y, Liu Z, Du Y and Yu Z: PIM2-mediated phosphorylation of
hexokinase 2 is critical for tumor growth and paclitaxel resistance
in breast cancer. Oncogene. 37:5997–6009. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan K, Fan Z, Cheng H, Huang Q, Yang C,
Jin K, Luo G, Yu X and Liu C: Hexokinase 2 dimerization and
interaction with voltage-dependent anion channel promoted
resistance to cell apoptosis induced by gemcitabine in pancreatic
cancer. Cancer Med. 8:5903–5915. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rai Y, Yadav P, Kumari N, Kalra N and
Bhatt AN: Hexokinase II inhibition by 3-bromopyruvate sensitizes
myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin.
Biosci Rep. 39:BSR201908802019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Tang X, Luo Y, Chen B, Zhou C, Wu X,
Tang Z, Qi X, Cao G, Hao J, et al: NK007 helps in mitigating
paclitaxel resistance through p38MAPK activation and HK2
degradation in ovarian cancer. J Cell Physiol. Feb 20–2019.(Epub
ahead of print).
|
|
21
|
Geng C, Li J, Ding F, Wu G, Yang Q, Sun Y,
Zhang Z, Dong T and Tian X: Curcumin suppresses 4-hydroxytamoxifen
resistance in breast cancer cells by targeting SLUG/Hexokinase 2
pathway. Biochem Biophys Res Commun. 473:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahammedi H, Planchat E, Pouget M, Durando
X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert
M, et al: The new combination docetaxel, prednisone and curcumin in
patients with castration-resistant prostate cancer: A pilot phase
II study. Oncology. 90:69–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gadducci A, Brunetti I, Muttini MP,
Fanucchi A, Dargenio F, Giannessi PG and Conte PF: Epidoxorubicin
and lonidamine in refractory or recurrent epithelial ovarian
cancer. Eur J Cancer. 30A:1432–1435. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De Lena M, Lorusso V, Latorre A, Fanizza
G, Gargano G, Caporusso L, Guida M, Catino A, Crucitta E, Sambiasi
D and Mazzei A: Paclitaxel, cisplatin and lonidamine in advanced
ovarian cancer. A phase II study. Eur J Cancer. 37:364–368. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang K, Liang Q, Zhou Y, Jiang LL, Gu WM,
Luo MY, Tang YB, Wang Y, Lu W, Huang M, et al: A novel allosteric
inhibitor of phosphoglycerate mutase 1 suppresses growth and
metastasis of non-small-cell lung cancer. Cell Metab.
30:1107–1119.e8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao
Y, Chen X, Zeng D, Tong A, Chen L, et al: Quantitative proteomics
identification of phosphoglycerate mutase 1 as a novel therapeutic
target in hepatocellular carcinoma. Mol Cancer. 9:812010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Usuba T, Ishibashi Y, Okawa Y, Hirakawa T,
Takada K and Ohkawa K: Purification and identification of
monoubiquitin-phosphoglycerate mutase B complex from human
colorectal cancer tissues. Int J Cancer. 94:662–668. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu L, Wang S, Zhang Q and Ding Y:
Identification of potential genes/proteins regulated by Tiam1 in
colorectal cancer by microarray analysis and proteome analysis.
Cell Biol Int. 32:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen G, Gharib TG, Wang H, Huang CC, Kuick
R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, et al:
Protein profiles associated with survival in lung adenocarcinoma.
Proc Natl Acad Sci USA. 100:13537–13542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen SY, Cai JX, Zhang WP, Zhang XW, Hu
SS, Lu J, Xing JF and Dong YL: Proteomic identification of
differentially expressed proteins associated with the multiple drug
resistance in methotrexate-resistant human breast cancer cells. Int
J Oncol. 45:448–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang HJ, Pochampalli M, Wang LY, Zou JX,
Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, et al:
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2
network and tumor metabolism in CRPC. Oncogene. 38:17–32. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qian Y, Bi L, Yang Y and Wang D: Effect of
pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy
resistance of estrogen receptor-positive breast cancer. Anticancer
Drugs. 29:616–627. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian S, Li P, Sheng S and Jin X:
Upregulation of pyruvate kinase M2 expression by fatty acid
synthase contributes to gemcitabine resistance in pancreatic
cancer. Oncol Lett. 15:2211–2217. 2018.PubMed/NCBI
|
|
34
|
Wong TL, Ng KY, Tan KV, Chan LH, Zhou L,
Che N, Hoo RLC, Lee TK, Richard S, Lo CM, et al: CRAF methylation
by PRMT6 regulates aerobic glycolysis driven hepatocarcinogenesis
via ERK-dependent PKM2 nuclear relocalization and activation.
Hepatology. 71:1279–1296. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng C, Xie Z, Li Y, Wang J, Qin C and
Zhang Y: PTBP1 knockdown overcomes the resistance to vincristine
and oxaliplatin in drug-resistant colon cancer cells through
regulation of glycolysis. Biomed Pharmacother. 108:194–200. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shang D, Wu J, Guo L, Xu Y, Liu L and Lu
J: Metformin increases sensitivity of osteosarcoma stem cells to
cisplatin by inhibiting expression of PKM2. Int J Oncol.
50:1848–1856. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ge X, Zhao Y, Dong L, Seng J, Zhang X and
Dou D: NAMPT regulates PKM2 nuclear location through 14-3-3 ζ:
Conferring resistance to tamoxifen in breast cancer. J Cell
Physiol. 234:23409–23420. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Calabretta S, Bielli P, Passacantilli I,
Pilozzi E, Fendrich V, Capurso G, Fave GD and Sette C: Modulation
of PKM alternative splicing by PTBP1 promotes gemcitabine
resistance in pancreatic cancer cells. Oncogene. 35:2031–2039.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang X, Zhang F and Wu XR: Inhibition of
pyruvate kinase M2 markedly reduces chemoresistance of advanced
bladder cancer to cisplatin. Sci Rep. 7:459832017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gatti M, Solari A, Pattarozzi A,
Campanella C, Thellung S, Maniscalco L, De Maria R, Würth R,
Corsaro A, Bajetto A, et al: In vitro and in vivo characterization
of stem-like cells from canine osteosarcoma and assessment of drug
sensitivity. Exp Cell Res. 363:48–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ramos-Penafiel C, Olarte-Carrillo I,
Ceron-Maldonado R, Rozen-Fuller E, Kassack-Ipiña JJ, Meléndez-Mier
G, Collazo-Jaloma J and Martínez-Tovar A: Effect of metformin on
the survival of patients with ALL who express high levels of the
ABCB1 drug resistance gene. J Transl Med. 16:2452018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shanmugasundaram K, Nayak BK, Friedrichs
WE, Kaushik D, Rodriguez R and Block K: NOX4 functions as a
mitochondrial energetic sensor coupling cancer metabolic
reprogramming to drug resistance. Nat Commun. 8:9972017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu CW, Lin SC, Chen KF, Lai YY and Tsai
SJ: Induction of pyruvate dehydrogenase kinase-3 by
hypoxia-inducible factor-1 promotes metabolic switch and drug
resistance. J Biol Chem. 283:28106–28114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang M, Cong Q, Zhang XY, Zhang MX, Lu YY
and Xu CJ: Pyruvate dehydrogenase kinase 1 contributes to cisplatin
resistance of ovarian cancer through EGFR activation. J Cell
Physiol. 234:6361–6370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu T, Yu S, Li Y, Ren H, Ning Q, Wang J,
Liang X and Li M: PDK2 induces cisplatin-resistance in lung
adenocarcinoma via transcriptional regulation of CNNM3. J Drug
Target. 27:460–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu CW, Lin SC, Chien CW, Lin SC, Lee CT,
Lin BW, Lee JC and Tsai SJ: Overexpression of pyruvate
dehydrogenase kinase 3 increases drug resistance and early
recurrence in colon cancer. Am J Pathol. 179:1405–1414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ren YJ, Wang XH, Ji C, Guan YD, Lu XJ, Liu
XR, Zhang HH, Guo LC, Xu QH, Zhu WD, et al: Silencing of NAC1
expression induces cancer cells oxidative stress in hypoxia and
potentiates the therapeutic activity of elesclomol. Front
Pharmacol. 8:8042017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Strowitzki MJ, Radhakrishnan P, Pavicevic
S, Scheer J, Kimmer G, Ritter AS, Tuffs C, Volz C, Vondran F,
Harnoss JM, et al: High hepatic expression of PDK4 improves
survival upon multimodal treatment of colorectal liver metastases.
Br J Cancer. 120:675–688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Walter W, Thomalla J, Bruhn J, Fagan DH,
Zehowski C, Yee D and Skildum A: Altered regulation of PDK4
expression promotes antiestrogen resistance in human breast cancer
cells. Springerplus. 4:6892015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Michelakis ED, Webster L and Mackey JR:
Dichloroacetate (DCA) as a potential metabolic-targeting therapy
for cancer. Br J Cancer. 99:989–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Woo SH, Seo SK, Park Y, Kim EK, Seong MK,
Kim HA, Song JY, Hwang SG, Lee JK, Noh WC and Park IC:
Dichloroacetate potentiates tamoxifen-induced cell death in breast
cancer cells via downregulation of the epidermal growth factor
receptor. Oncotarget. 7:59809–59819. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xuan Y, Hur H, Ham IH, Yun J, Lee JY, Shim
W, Kim YB, Lee G, Han SU and Cho YK: Dichloroacetate attenuates
hypoxia-induced resistance to 5-fluorouracil in gastric cancer
through the regulation of glucose metabolism. Exp Cell Res.
321:219–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Clayton: Case of ulceration of the larynx.
Med Phys J. 32:25–26. 1814.PubMed/NCBI
|
|
54
|
Lu H, Lu Y, Xie Y, Qiu S, Li X and Fan Z:
Rational combination with PDK1 inhibition overcomes cetuximab
resistance in head and neck squamous cell carcinoma. JCI Insight.
4:e1311062019. View Article : Google Scholar
|
|
55
|
Yang Z and Tam KY: Anti-cancer synergy of
dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell
lines. Eur J Pharmacol. 789:458–467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xue X, You S, Zhang Q, Wu Y, Zou GZ, Wang
PC, Zhao YL, Xu Y, Jia L, Zhang X and Liang XJ: Mitaplatin
increases sensitivity of tumor cells to cisplatin by inducing
mitochondrial dysfunction. Mol Pharm. 9:634–644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang Z, Zhang SL, Hu X and Tam KY:
Inhibition of pyruvate dehydrogenase kinase 1 enhances the
anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small
cell lung cancer. Eur J Pharmacol. 838:41–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pardee TS, Luther S, Buyse M, Powell BL
and Cortes J: Devimistat in combination with high dose cytarabine
and mitoxantrone compared with high dose cytarabine and
mitoxantrone in older patients with relapsed/refractory acute
myeloid leukemia: ARMADA 2000 Phase III study. Future Oncol.
15:3197–3208. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ding J, Karp JE and Emadi A: Elevated
lactate dehydrogenase (LDH) can be a marker of immune suppression
in cancer: Interplay between hematologic and solid neoplastic
clones and their microenvironments. Cancer Biomark. 19:353–363.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Muramatsu H, Sumitomo M, Morinaga S,
Kajikawa K, Kobayashi I, Nishikawa G, Kato Y, Watanabe M, Zennami
K, Kanao K, et al: Targeting lactate dehydrogenase-A promotes
docetaxel-induced cytotoxicity predominantly in
castration-resistant prostate cancer cells. Oncol Rep. 42:224–230.
2019.PubMed/NCBI
|
|
62
|
Nagamine A, Araki T, Nagano D, Miyazaki M
and Yamamoto K: L-Lactate dehydrogenase B may be a predictive
marker for sensitivity to anti-EGFR monoclonal antibodies in
colorectal cancer cell lines. Oncol Lett. 17:4710–4716.
2019.PubMed/NCBI
|
|
63
|
Feng L, E LL, Soloveiv MM, Wang DS, Zhang
BO, Dong YW and Liu HC: Synergistic cytotoxicity of cisplatin and
Taxol in overcoming Taxol resistance through the inhibition of LDHA
in oral squamous cell carcinoma. Oncol Lett. 9:1827–1832. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hua G, Liu Y, Li X, Xu P and Luo Y:
Targeting glucose metabolism in chondrosarcoma cells enhances the
sensitivity to doxorubicin through the inhibition of lactate
dehydrogenase-A. Oncol Rep. 31:2727–2734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Bougioukas G, Didilis V, Gatter KC and Harris AL: Lactate
dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung
cancer tissues is linked to tumour hypoxia, angiogenic factor
production and poor prognosis. Br J Cancer. 89:877–885. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lu H, Li X, Luo Z, Liu J and Fan Z:
Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated
LDH-A. Mol Cancer Ther. 12:2187–2199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu X, Yao D, Liu C, Cao Y, Yang Q, Sun Z
and Liu D: Overexpression of ABCC3 promotes cell proliferation,
drug resistance, and aerobic glycolysis and is associated with poor
prognosis in urinary bladder cancer patients. Tumour Biol.
37:8367–8374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Aggarwal A and Keluskar V: Epithelioid
hemangioma (angiolymphoid hyperplasia with eosinophilia) in the
oral mucosa. Indian J Dent Res. 23:271–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hamadneh L, Abuarqoub R, Alhusban A and
Bahader M: Upregulation of PI3K/AKT/PTEN pathway is correlated with
glucose and glutamine metabolic dysfunction during tamoxifen
resistance development in MCF-7 cells. Sci Rep. 10:219332020.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sun H, Wang H and Wang X, Aoki Y and Wang
X, Yang Y, Cheng X, Wang Z and Wang X: Aurora-A/SOX8/FOXK1
signaling axis promotes chemoresistance via suppression of cell
senescence and induction of glucose metabolism in ovarian cancer
organoids and cells. Theranostics. 10:6928–6945. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dong D, Ko B, Baumeister P, Swenson S,
Costa F, Markland F, Stiles C, Patterson JB, Bates SE and Lee AS:
Vascular targeting and antiangiogenesis agents induce drug
resistance effector GRP78 within the tumor microenvironment. Cancer
Res. 65:5785–5791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lee E, Nichols P, Spicer D, Groshen S, Yu
MC and Lee AS: GRP78 as a novel predictor of responsiveness to
chemotherapy in breast cancer. Cancer Res. 66:7849–7853. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhou H, Zhang Y, Fu Y, Chan L and Lee AS:
Novel mechanism of anti-apoptotic function of 78-kDa
glucose-regulated protein (GRP78): Endocrine resistance factor in
breast cancer, through release of B-cell lymphoma 2 (BCL-2) from
BCL-2-interacting killer (BIK). J Biol Chem. 286:25687–25696. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cristanziano VD, Bottcher S, Diedrich S,
Timmen-Wego M, Knops E, Lübke N, Kaiser R, Pfister H, Kaboré Y and
D'Alfonso R: Detection and characterization of enteroviruses and
parechoviruses in healthy people living in the South of Cote
d'Ivoire. J Clin Virol. 71:40–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cheng Y, Diao D, Zhang H, Guo Q, Wu X,
Song Y and Dang C: High glucose-induced resistance to
5-fluorouracil in pancreatic cancer cells alleviated by
2-deoxy-D-glucose. Biomed Rep. 2:188–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Panizo C, Perez-Salazar M, Bendandi M,
Rodríguez-Calvillo M, Boán JF, García-Velloso MJ, Richter J and
Rocha E: Positron emission tomography using 18F-fluorodeoxyglucose
for the evaluation of residual Hodgkin's disease mediastinal
masses. Leuk Lymphoma. 45:1829–1833. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Weber WA, Ott K, Becker K, Dittler HJ,
Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR,
Schwaiger M and Fink U: Prediction of response to preoperative
chemotherapy in adenocarcinomas of the esophagogastric junction by
metabolic imaging. J Clin Oncol. 19:3058–3065. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Gallamini A, Rigacci L, Merli F, Nassi L,
Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E,
et al: The predictive value of positron emission tomography
scanning performed after two courses of standard therapy on
treatment outcome in advanced stage Hodgkin's disease.
Haematologica. 91:475–481. 2006.PubMed/NCBI
|
|
79
|
Chen LQ, Cheung LS, Feng L, Tanner W and
Frommer WB: Transport of sugars. Annu Rev Biochem. 84:865–894.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Reckzeh ES and Waldmann H: Small-Molecule
inhibition of glucose transporters GLUT-1-4. Chembiochem. 21:45–52.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mayer A, Hockel M, Wree A and Vaupel P:
Microregional expression of glucose transporter-1 and oxygenation
status: Lack of correlation in locally advanced cervical cancers.
Clin Cancer Res. 11:2768–2773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Suzuki S, Okada M, Takeda H, Kuramoto K,
Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T and
Kitanaka C: Involvement of GLUT1-mediated glucose transport and
metabolism in gefitinib resistance of non-small-cell lung cancer
cells. Oncotarget. 9:32667–32679. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang T, Ning K, Sun X, Zhang C, Jin LF and
Hua D: Glycolysis is essential for chemoresistance induced by
transient receptor potential channel C5 in colorectal cancer. BMC
Cancer. 18:2072018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Guan DG, Chen HM, Liao SF and Zhao TZ:
Combination of temozolomide and Taxol exerts a synergistic
inhibitory effect on Taxolresistant glioma cells via inhibition of
glucose metabolism. Mol Med Rep. 12:7705–7711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu PJ, Ma F, Lou HP, Zhu YN and Chen Y:
Relationship between serum uric acid levels and metabolic syndrome
in Chinese postmenopausal women. Climacteric. 17:148–154. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang L, Sun J, Gao P, Su K, Wu H, Li J and
Lou W: Wnt1-inducible signaling protein 1 regulates laryngeal
squamous cell carcinoma glycolysis and chemoresistance via the
YAP1/TEAD1/GLUT1 pathway. J Cell Physiol. Feb 25–2019.(Epub ahead
of print).
|
|
87
|
Li S, Li J, Dai W, Zhang Q, Feng J, Wu L,
Liu T, Yu Q, Xu S, Wang W, et al: Genistein suppresses aerobic
glycolysis and induces hepatocellular carcinoma cell death. Br J
Cancer. 117:1518–1528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Gou Q, Dong C, Jin J, Liu Q, Lu W, Shi J
and Hou Y: PPARα agonist alleviates tumor growth and
chemo-resistance associated with the inhibition of glucose
metabolic pathway. Eur J Pharmacol. 863:1726642019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhou Y, Wen H, Gu L, Fu J, Guo J, Du L,
Zhou X, Yu X, Huang Y and Wang H: Aminoglucose-functionalized,
redox-responsive polymer nanomicelles for overcoming
chemoresistance in lung cancer cells. J Nanobiotechnology.
15:872017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
91
|
Kim JW and Dang CV: Cancer's molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen Z, Lu W, Garcia-Prieto C and Huang P:
The Warburg effect and its cancer therapeutic implications. J
Bioenerg Biomembr. 39:267–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wagner W, Ciszewski WM and Kania KD: L-
and D-lactate enhance DNA repair and modulate the resistance of
cervical carcinoma cells to anticancer drugs via histone
deacetylase inhibition and hydroxycarboxylic acid receptor 1
activation. Cell Commun Signal. 13:362015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Granja S, Tavares-Valente D, Queiros O and
Baltazar F: Value of pH regulators in the diagnosis, prognosis and
treatment of cancer. Semin Cancer Biol. 43:17–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Doyen J, Parks SK, Marcie S, Pouyssegur J
and Chiche J: Knock-down of hypoxia-induced carbonic anhydrases IX
and XII radiosensitizes tumor cells by increasing intracellular
acidosis. Front Oncol. 2:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Dubois L, Peeters S, Lieuwes NG, Geusens
N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogné
JM, et al: Specific inhibition of carbonic anhydrase IX activity
enhances the in vivo therapeutic effect of tumor irradiation.
Radiother Oncol. 99:424–431. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Betof AS, Rabbani ZN, Hardee ME, Kim SJ,
Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E,
Harris LN, et al: Carbonic anhydrase IX is a predictive marker of
doxorubicin resistance in early-stage breast cancer independent of
HER2 and TOP2A amplification. Br J Cancer. 106:916–922. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Aomatsu N, Yashiro M, Kashiwagi S,
Kawajiri H, Takashima T, Ohsawa M, Wakasa K and Hirakawa K:
Carbonic anhydrase 9 is associated with chemosensitivity and
prognosis in breast cancer patients treated with taxane and
anthracycline. BMC Cancer. 14:4002014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Rauch C: On the relationship between
drug's size, cell membrane mechanical properties and high levels of
multi drug resistance: A comparison to published data. Eur Biophys
J. 38:537–546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Perez-Sayans M, Somoza-Martin JM,
Barros-Angueira F, Diz PG, Rey JM and Garcia-Garcia A: Multidrug
resistance in oral squamous cell carcinoma: The role of vacuolar
ATPases. Cancer Lett. 295:135–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Larsen AK, Escargueil AE and Skladanowski
A: Resistance mechanisms associated with altered intracellular
distribution of anticancer agents. Pharmacol Ther. 85:217–229.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Le Floch R, Chiche J, Marchiq I, Naiken T,
Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP and Pouysségur J:
CD147 subunit of lactate/H+ symporters MCT1 and
hypoxia-inducible MCT4 is critical for energetics and growth of
glycolytic tumors. Proc Natl Acad Sci USA. 108:16663–16668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Boidot R, Vegran F, Meulle A, Le Breton A,
Dessy C, Sonveaux P, Lizard-Nacol S and Feron O: Regulation of
monocarboxylate transporter MCT1 expression by p53 mediates inward
and outward lactate fluxes in tumors. Cancer Res. 72:939–948. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Saenz-de-Santa-Maria I,
Bernardo-Castineira C, Secades P, Bernaldo-de-Quirós S, Rodrigo JP,
Astudillo A and Chiara MD: Clinically relevant HIF-1α-dependent
metabolic reprogramming in oropharyngeal squamous cell carcinomas
includes coordinated activation of CAIX and the miR-210/ISCU
signaling axis, but not MCT1 and MCT4 upregulation. Oncotarget.
8:13730–13746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Draoui N, Schicke O, Seront E, Bouzin C,
Sonveaux P, Riant O and Feron O: Antitumor activity of
7-aminocarboxycoumarin derivatives, a new class of potent
inhibitors of lactate influx but not efflux. Mol Cancer Ther.
13:1410–1418. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Li QX, Zhang P, Liu F, Wang XZ, Li L, Wang
ZK, Jiang CC, Zheng HL and Liu H: Monocarboxylate transporter 1
enhances the sensitivity of breast cancer cells to 3-bromopyruvate
in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 37:588–593. 2017.(In
Chinese). PubMed/NCBI
|
|
107
|
Pisarsky L, Bill R, Fagiani E, Dimeloe S,
Goosen RW, Hagmann J, Hess C and Christofori G: Targeting metabolic
symbiosis to overcome resistance to anti-angiogenic therapy. Cell
Rep. 15:1161–1174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Khammanivong A, Saha J, Spartz AK,
Sorenson BS, Bush AG, Korpela DM, Gopalakrishnan R, Jonnalagadda S,
Mereddy VR, O'Brien TD, et al: A novel MCT1 and MCT4 dual inhibitor
reduces mitochondrial metabolism and inhibits tumour growth of
feline oral squamous cell carcinoma. Vet Comp Oncol. 8:324–341.
2020. View Article : Google Scholar
|
|
109
|
Andreucci E, Ruzzolini J, Peppicelli S,
Bianchini F, Laurenzana A, Carta F, Supuran CT and Calorini L: The
carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to
conventional chemotherapy. J Enzyme Inhib Med Chem. 34:117–123.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tan EY, Yan M, Campo L, Han C, Takano E,
Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, et al: The
key hypoxia regulated gene CAIX is upregulated in basal-like breast
tumours and is associated with resistance to chemotherapy. Br J
Cancer. 100:405–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zheng G, Peng C, Jia X, Gu Y, Zhang Z,
Deng Y, Wang C, Li N, Yin J, Liu X, et al: ZEB1 transcriptionally
regulated carbonic anhydrase 9 mediates the chemoresistance of
tongue cancer via maintaining intracellular pH. Mol Cancer.
14:842015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Takahashi E, Abe J and Berk BC:
Angiotensin II stimulates p90rsk in vascular smooth muscle cells. A
potential Na(+)-H+ exchanger kinase. Circ Res.
81:268–273. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Altaf E, Huang X, Xiong J, Yang X, Deng X,
Xiong M, Zhou L, Pan S, Yuan W, Li X, et al: NHE1 has a notable
role in metastasis and drug resistance of T-cell acute
lymphoblastic leukemia. Oncol Lett. 14:4256–4262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chen Q, Liu Y, Zhu XL, Feng F, Yang H and
Xu W: Increased NHE1 expression is targeted by specific inhibitor
cariporide to sensitize resistant breast cancer cells to
doxorubicin in vitro and in vivo. BMC Cancer. 19:2112019.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Paskeviciute M and Petrikaite V:
Overcoming transporter-mediated multidrug resistance in cancer:
Failures and achievements of the last decades. Drug Deliv Transl
Res. 9:379–393. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Park S, Chang CY, Safi R, Liu X, Baldi R,
Jasper JS, Anderson GR, Liu T, Rathmell JC, Dewhirst MW, et al:
ERRα-Regulated lactate metabolism contributes to resistance to
targeted therapies in breast cancer. Cell Rep. 15:323–335. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yu T, Yang G, Hou Y, Tang X, Wu C, Wu XA,
Guo L, Zhu Q, Luo H, Du YE, et al: Cytoplasmic GPER translocation
in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic
axis to confer tumor cells with multidrug resistance. Oncogene.
36:2131–2145. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kalbasi A and Ribas A: Tumour-intrinsic
resistance to immune checkpoint blockade. Nat Rev Immunol.
20:25–39. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 19:1189–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Liang X, Fu C, Cui W, Ober-Blöbaum JL,
Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I and Jiang
A: β-catenin mediates tumor-induced immunosuppression by inhibiting
cross-priming of CD8+ T cells. J Leukoc Biol.
95:179–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C,
Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of
PTEN promotes resistance to T cell-mediated immunotherapy. Cancer
Discov. 6:202–216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He
Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al: Loss of IFN-ү
pathway genes in tumor cells as a mechanism of resistance to
anti-CTLA-4 therapy. Cell. 167:397–404.e9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Pitroda SP, Wakim BT, Sood RF, Beveridge
MG, Beckett MA, MacDermed DM, Weichselbaum RR and Khodarev NN:
STAT1-dependent expression of energy metabolic pathways links
tumour growth and radioresistance to the warburg effect. BMC Med.
7:682009. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Poli V and Camporeale A: STAT3-mediated
metabolic reprograming in cellular transformation and implications
for drug resistance. Front Oncol. 5:1212015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Cascone T, McKenzie JA, Mbofung RM, Punt
S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, et al:
Increased tumor glycolysis characterizes immune resistance to
adoptive T cell therapy. Cell Metab. 27:977–987.e4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Sacchi S, Federico M, Vitolo U, Boccomini
C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli
F, et al: Clinical activity and safety of combination immunotherapy
with IFN-alpha 2a and Rituximab in patients with relapsed low grade
non-Hodgkin's lymphoma. Haematologica. 86:951–958. 2001.PubMed/NCBI
|
|
127
|
Davis TA, Maloney DG, Grillo-Lopez AJ,
White CA, Williams ME, Weiner GJ, Dowden S and Levy R: Combination
immunotherapy of relapsed or refractory low-grade or follicular
non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin
Cancer Res. 6:2644–2652. 2000.PubMed/NCBI
|
|
128
|
Rosenberg SA, Lotze MT, Yang JC, Linehan
WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S and White
DE: Combination therapy with interleukin-2 and alpha-interferon for
the treatment of patients with advanced cancer. J Clin Oncol.
7:1863–1874. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Magalhaes I, Yogev O, Mattsson J and
Schurich A: The metabolic profile of tumor and virally infected
cells shapes their microenvironment counteracting T cell immunity.
Front Immunol. 10:23092019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Pate KT, Stringari C, Sprowl-Tanio S, Wang
K, TeSlaa T, Hoverter NP, McQuade MM, Garner C, Digman MA, Teitell
MA, et al: Wnt signaling directs a metabolic program of glycolysis
and angiogenesis in colon cancer. EMBO J. 33:1454–1473. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yang L, Perez AA, Fujie S, Warden C, Li J,
Wang Y, Yung B, Chen YR, Liu X, Zhang H, et al: Wnt modulates MCL1
to control cell survival in triple negative breast cancer. BMC
Cancer. 14:1242014. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sprowl-Tanio S, Habowski AN, Pate KT,
McQuade MM, Wang K, Edwards RA, Grun F, Lyou Y and Waterman ML:
Lactate/pyruvate transporter MCT-1 is a direct Wnt target that
confers sensitivity to 3-bromopyruvate in colon cancer. Cancer
Metab. 4:202016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Feng M, Jin JQ, Xia L, Xiao T, Mei S, Wang
X, Huang X, Chen J, Liu M, Chen C, et al: Pharmacological
inhibition of β-catenin/BCL9 interaction overcomes resistance to
immune checkpoint blockades by modulating Treg cells.
Sci Adv. 5:eaau52402019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
George S, Miao D, Demetri GD, Adeegbe D,
Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter
SL, et al: Loss of PTEN is associated with resistance to Anti-PD-1
checkpoint blockade therapy in metastatic uterine leiomyosarcoma.
Immunity. 46:197–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ramapriyan R, Caetano MS, Barsoumian HB,
Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW and Cortez MA:
Altered cancer metabolism in mechanisms of immunotherapy
resistance. Pharmacol Ther. 195:162–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jabbarzadeh Kaboli P, Salimian F, Aghapour
S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, et al:
Akt-targeted therapy as a promising strategy to overcome drug
resistance in breast cancer-A comprehensive review from
chemotherapy to immunotherapy. Pharmacol Res. 156:1048062020.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Blagden SP, Hamilton AL, Mileshkin L, Wong
S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou
E, et al: Phase IB dose escalation and expansion study of AKT
inhibitor afuresertib with carboplatin and paclitaxel in recurrent
platinum-resistant ovarian cancer. Clin Cancer Res. 25:1472–1478.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Tammela T, Sanchez-Rivera FJ, Cetinbas NM,
Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft
RA, et al: A Wnt-producing niche drives proliferative potential and
progression in lung adenocarcinoma. Nature. 545:355–359. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
de Bono JS, De Giorgi U, Rodrigues DN,
Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi
GD, Xu N, et al: Randomized phase II study evaluating Akt blockade
with ipatasertib, in combination with abiraterone, in patients with
metastatic prostate cancer with and without PTEN loss. Clin Cancer
Res. 25:928–936. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Kunkl M, Sambucci M, Ruggieri S, Amormino
C, Tortorella C, Gasperini C, Battistini L and Tuosto L: CD28
autonomous signaling Up-regulates C-Myc expression and promotes
glycolysis enabling inflammatory T cell responses in multiple
sclerosis. Cells. 8:5752019. View Article : Google Scholar
|
|
141
|
Chen F, Chen J, Yang L, Liu J, Zhang X,
Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al: Extracellular
vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated
macrophages regulates aerobic glycolysis of breast cancer cells.
Nat Cell Biol. 21:498–510. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Xie G, Liu Y, Yao Q, Zheng R, Zhang L, Lin
J, Guo Z, Du S, Ren C, Yuan Q and Yuan Y: Hypoxia-induced
angiotensin II by the lactate-chymase-dependent mechanism mediates
radioresistance of hypoxic tumor cells. Sci Rep. 7:423962017.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Xie G, Cheng T, Lin J, Zhang L, Zheng J,
Liu Y, Xie G, Wang B and Yuan Y: Local angiotensin II contributes
to tumor resistance to checkpoint immunotherapy. J Immunother
Cancer. 6:882018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Fischer K, Hoffmann P, Voelkl S,
Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G,
Hoves S, et al: Inhibitory effect of tumor cell-derived lactic acid
on human T cells. Blood. 109:3812–3819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Ohashi T, Akazawa T, Aoki M, Kuze B,
Mizuta K, Ito Y and Inoue N: Dichloroacetate improves immune
dysfunction caused by tumor-secreted lactic acid and increases
antitumor immunoreactivity. Int J Cancer. 133:1107–1118. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Bosc C, Selak MA and Sarry JE: Resistance
is futile: Targeting mitochondrial energetics and metabolism to
overcome drug resistance in cancer treatment. Cell Metab.
26:705–707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Alexa-Stratulat T, Pesic M, Gasparovic AC,
Trougakos IP and Riganti C: What sustains the multidrug resistance
phenotype beyond ABC efflux transporters? Looking beyond the tip of
the iceberg. Drug Resist Updat. 46:1006432019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Roth KG, Mambetsariev I, Kulkarni P and
Salgia R: The mitochondrion as an emerging therapeutic target in
cancer. Trends Mol Med. 26:119–134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Farge T, Saland E, de Toni F, Aroua N,
Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, et al:
Chemotherapy-resistant human acute myeloid leukemia cells are not
enriched for leukemic stem cells but require oxidative metabolism.
Cancer Discov. 7:716–735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Migneco G, Whitaker-Menezes D, Chiavarina
B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg
N, Tsirigos A, Howell A, et al: Glycolytic cancer associated
fibroblasts promote breast cancer tumor growth, without a
measurable increase in angiogenesis: Evidence for
stromal-epithelial metabolic coupling. Cell Cycle. 9:2412–2422.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ricci F, Brunelli L, Affatato R, Chilà R,
Verza M, Indraccolo S, Falcetta F, Fratelli M, Fruscio R,
Pastorelli R and Damia G: Overcoming platinum-acquired resistance
in ovarian cancer patient-derived xenografts. Ther Adv Med Oncol.
11:17588359198395432019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wu L, Zhao J, Cao K, Liu X, Cai H, Wang J,
Li W and Chen Z: Oxidative phosphorylation activation is an
important characteristic of DOX resistance in hepatocellular
carcinoma cells. Cell Commun Signal. 16:62018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lee KM, Giltnane JM, Balko JM, Schwarz LJ,
Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V,
Sanders ME, et al: MYC and MCL1 cooperatively promote
chemotherapy-resistant breast cancer stem cells via regulation of
mitochondrial oxidative phosphorylation. Cell Metab. 26:633–647.e7.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chen CL, Uthaya Kumar DB, Punj V, Xu J,
Sher L, Tahara SM, Hess S and Machida K: NANOG metabolically
reprograms tumor-initiating stem-like cells through tumorigenic
changes in oxidative phosphorylation and fatty acid metabolism.
Cell Metab. 23:206–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Andreucci E, Pietrobono S, Peppicelli S,
Ruzzolini J, Bianchini F, Biagioni A, Stecca B and Calorini L: SOX2
as a novel contributor of oxidative metabolism in melanoma cells.
Cell Commun Signal. 16:872018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Choi HJ, Jhe YL, Kim J, Lim JY, Lee JE,
Shin MK and Cheong JH: FoxM1-dependent and fatty acid
oxidation-mediated ROS modulation is a cell-intrinsic drug
resistance mechanism in cancer stem-like cells. Redox Biol.
36:1015892020. View Article : Google Scholar : PubMed/NCBI
|
